Topical calcipotriol for preventive treatment of hypertrophic scars: A randomized, double-blind, placebo-controlled trial

Archives of Dermatology

Volumn 145, Issue 11, 2009, Pages 1269-1275

  Van Der Veer, Willem M ^a   Jacobs, Xander E ^a   Waardenburg, Ingmar E ^b   Ulrich, Magda M ^a,c   Niessen, Frank B ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Association of Dutch Burn Centers   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; CYTOKERATIN 16; KI 67 ANTIGEN; PLACEBO; T6 ANTIGEN;

ADULT; ARTICLE; BREAST REDUCTION; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; HUMAN; HYPERTROPHIC SCAR; IMMUNOHISTOCHEMISTRY; INCIDENCE; KERATINOCYTE; NETHERLANDS; PRIORITY JOURNAL; PROPHYLAXIS; PUNCH BIOPSY; SCAR FORMATION; SCORING SYSTEM; SKIN IRRITATION; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; BIOPSY, NEEDLE; CALCITRIOL; CICATRIX, HYPERTROPHIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMAPLASTY; MIDDLE AGED; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER; WOUND HEALING; YOUNG ADULT;

EID: 72749104603     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.237     Document Type: Article

References (33)

1. Niessen FB, Spauwen PH, Robinson PH, Fidler V, Kon M. The use of silicone occlusive sheeting (Sil-K) and silicone occlusive gel (Epiderm) in the prevention of hypertrophic scar formation. Plast Reconstr Surg. 1998;102(6):1962-1972. (Pubitemid 28518520)
2. Spurr ED, Shakespeare PG. Incidence of hypertrophic scarring in burn-injured children. Burns. 1990;16(3):179-181.
3. Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg. 1999;104(5):1435-1458. (Pubitemid 29466295)
4. Saulis AS, Mogford JH, Mustoe TA. Effect of Mederma on hypertrophic scarring in the rabbit ear model. Plast Reconstr Surg. 2002;110(1):177-183, discussion 184-186. (Pubitemid 34686267)
5. Singer AJ, McClain SA. Persistent wound infection delays epidermal maturation and increases scarring in thermal burns. Wound Repair Regen. 2002;10(6):372-377.
6. van der Veer WM, Bloemen MC, Ulrich MM, et al. Potential cellular and molecular causes of hypertrophic scar formation. Burns. 2009;35(1):15-29.
7. Morris DE, Wu L, Zhao LL, et al. Acute and chronic animal models for excessive dermal scarring: quantitative studies. Plast Reconstr Surg. 1997;100(3):674-681. (Pubitemid 27381074)
8. Wilgus TA, Vodovotz Y, Vittadini E, Clubbs EA, Oberyszyn TM. Reduction of scar formation in full-thickness wounds with topical celecoxib treatment. Wound Repair Regen. 2003;11(1):25-34. (Pubitemid 36268606)
9. Andriessen MP, Niessen FB, Van de Kerkhof PC, Schalkwijk J. Hypertrophic scarring is associated with epidermal abnormalities: an immunohistochemical study. J Pathol. 1998;186(2):192-200. (Pubitemid 28467830)
10. Machesney M, Tidman N, Waseem A, Kirby L, Leigh I. Activated keratinocytes in the epidermis of hypertrophic scars. Am J Pathol. 1998;152(5):1133-1141. (Pubitemid 28221864)
11. Niessen FB, Andriessen MP, Schalkwijk J, Visser L, Timens W. Keratinocyte-derived growth factors play a role in the formation of hypertrophic scars. J Pathol. 2001;194(2):207-216. (Pubitemid 32519970)
12. Niessen FB, Schalkwijk J, Vos H, Timens W. Hypertrophic scar formation is associated with an increased number of epidermal Langerhans cells. J Pathol. 2004;202(1):121-129. (Pubitemid 38072853)
13. Freedberg IM, Tomic-Canic M, Komine M, Blumenberg M. Keratins and the keratinocyte activation cycle. J Invest Dermatol. 2001;116(5):633-640.
14. Bowcock AM, Krueger JG. Getting under the skin: the immunogenetics of psoriasis [published correction appears in Nat Rev Immunol. 2005;5(10):826]. Nat Rev Immunol. 2005;5(9):699-711.
15. Ashcroft DM, Po AL, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ. 2000;320(7240):963-967. (Pubitemid 30192863)
16. Kragballe K, Gjertsen BT, De Hoop D, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris [published correction appears in Lancet. 1991;337(8747):988]. Lancet. 1991;337(8735):193-196.
17. Kragballe K, Wildfang IL. Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res. 1990;282(3):164-167. (Pubitemid 20155219)
18. Dam TN, Møller B, Hindkjaer J, Kragballe K. The vitamin D3 analog calcipotriol suppresses the number and antigen-presenting function of Langerhans cells in normal human skin. J Investig Dermatol Symp Proc. 1996;1(1):72-77. (Pubitemid 126759346)
19. Cheng W, Saing H, Zhou H, Han Y, Peh W, Tam PK. Ultrasound assessment of scald scars in Asian children receiving pressure garment therapy. J Pediatr Surg. 2001;36(3):466-469. (Pubitemid 32193738)
20. van Zuijlen PP, Angeles AP, Kreis RW, Bos KE, Middelkoop E. Scar assessment tools: implications for current research. Plast Reconstr Surg. 2002;109(3):1108-1122. (Pubitemid 34206258)
21. Deitch EA, Wheelahan TM, Rose MP, Clothier J, Cotter J. Hypertrophic burn scars: analysis of variables. J Trauma. 1983;23(10):895-898.
22. Graves DT, Nooh N, Gillen T, et al. IL-1 plays a critical role in oral, but not dermal, wound healing. J Immunol. 2001;167(9):5316-5320. (Pubitemid 33009770)
23. Maas-Szabowski N, Szabowski A, Stark HJ, et al. Organotypic cocultures with genetically modified mouse fibroblasts as a tool to dissect molecular mechanisms regulating keratinocyte growth and differentiation. J Invest Dermatol. 2001;116(5):816-820. (Pubitemid 32467667)
24. Szabowski A, Maas-Szabowski N, Andrecht S, et al. c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell. 2000;103(5):745-755.
25. Morasso MI, Tomic-Canic M. Epidermal stem cells: the cradle of epidermal determination, differentiation and wound healing. Biol Cell. 2005;97(3):173-183. (Pubitemid 40360890)
26. Coulombe PA. Wound epithelialization: accelerating the pace of discovery. J Invest Dermatol. 2003;121(2):219-230.
27. Castagnoli C, Trombotto C, Ondei S, et al. Characterization of T-cell subsets infiltrating post-burn hypertrophic scar tissues. Burns. 1997;23(7-8):565-572. (Pubitemid 28142378)
28. Shah M, Foreman DM, Ferguson MW. Control of scarring in adult wounds by neutralising antibody to transforming growth factor β. Lancet. 1992;339(8787):213-214.
29. Hakvoort TE, Altun V, Ramrattan RS, et al. Epidermal participation in post-burn hypertrophic scar development. Virchows Arch. 1999;434(3):221-226. (Pubitemid 29186806)
30. Binderup L, Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol. 1988;37(5):889-895. (Pubitemid 18058461)
31. Kristl J, Slanc P, Krasna M, Berlec A, Jeras M, Strukelj B. Calcipotriol affects keratinocyte proliferation by decreasing expression of early growth response-1 and polo-like kinase-2. Pharm Res. 2008;25(3):521-529. (Pubitemid 351357721)
32. Lee E, Jeon SH, Yi JY, Jin YJ, Son YS. Calcipotriol inhibits autocrine phosphorylation of EGF receptor in a calcium-dependent manner, a possible mechanism for its inhibition of cell proliferation and stimulation of cell differentiation. Biochem Biophys Res Commun. 2001;284(2):419-425. (Pubitemid 32923059)
33. Zeeuwen PL, de Jongh GJ, Rodijk-Olthuis D, et al. Genetically programmed differences in epidermal host defense between psoriasis and atopic dermatitis patients. PLoS One. 2008;3(6):e2301 doi:10.1371/journal.pone.0002301. Accessed April 4, 2009.